{{.infobox .infobox-gene}}
| Symbol | YWHAH |
| Full Name | Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Eta |
| Chromosome | 22q12.3 |
| NCBI Gene ID | 7535 |
| OMIM | 608456 |
| Ensembl ID | ENSG00000128245 |
| UniProt ID | Q9Y2H5 |
| Associated Diseases | AD, PD, schizophrenia, CJD |
The YWHAH gene encodes the eta (η) isoform of 14-3-3 proteins, a highly conserved family of adaptor molecules that play critical roles in regulating cellular signaling, apoptosis, and neuronal function[1]. The 14-3-3 protein family consists of seven isoforms (beta, gamma, epsilon, zeta, eta, theta, sigma) that are expressed in all eukaryotic cells[2]. In the central nervous system, 14-3-3 proteins are particularly abundant and serve essential functions in neuronal survival, synaptic plasticity, and protection against neurodegenerative processes[3].
YWHAH is predominantly expressed in brain tissue, with high levels in the cerebral cortex, hippocampus, cerebellum, and substantia nigra[4]. The protein functions as a molecular scaffold and adaptor, binding to phosphorylated serine/threonine motifs on target proteins to modulate their activity, localization, and stability[5]. This broad regulatory capacity positions 14-3-3 proteins as central players in cellular homeostasis and neuroprotection.
14-3-3 eta is particularly important in the context of neurodegeneration. The protein has been shown to interact with key pathological proteins including tau, alpha-synuclein (SNCA, and various pro-apoptotic factors[6]. Alterations in 14-3-3 expression and function have been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and several other neurological disorders[2:1].
The YWHAH gene is located on chromosome 22q12.3 and spans approximately 35 kb. The gene consists of 6 exons encoding a 246-amino acid protein with a molecular weight of approximately 28 kDa[5:1]. The protein adopts a cup-like dimeric structure, with each monomer capable of binding to distinct target proteins, enabling the 14-3-3 dimer to serve as a molecular bridge between two different signaling molecules.
The 14-3-3 eta protein possesses several key structural characteristics:
YWHAH undergoes various post-translational modifications that regulate its function:
One of the most critical functions of 14-3-3 eta is its anti-apoptotic activity in neurons[7]. The protein exerts neuroprotective effects through multiple mechanisms:
Inhibition of pro-apoptotic proteins: YWHAH binds to and sequesters pro-apoptotic Bcl-2 family proteins including BAD (Bcl-2-associated agonist of cell death) and BAX (Bcl-2-associated X protein)[6:1]. By preventing BAD translocation to mitochondria and inhibiting BAX activation, 14-3-3 eta maintains mitochondrial membrane integrity and prevents cytochrome c release.
Caspase inhibition: 14-3-3 proteins can directly inhibit caspase activation cascades, particularly caspase-3 and caspase-9, key executors of apoptotic cell death[7:1].
p53 regulation: YWHAH binds to p53 and modulates its transcriptional activity, influencing the expression of pro-apoptotic genes[5:2].
14-3-3 eta participates in several critical neuronal signaling pathways:
YWHAH regulates the MAPK (mitogen-activated protein kinase) / ERK (extracellular signal-regulated kinase) pathway, which is essential for neuronal survival, differentiation, and plasticity[8]. The protein interacts with:
This modulation affects downstream transcription factors including ELK-1 and CREB, which are critical for activity-dependent gene expression in neurons.
The PI3K/Akt pathway is a major pro-survival signaling cascade in neurons. 14-3-3 eta modulates this pathway by:
This pathway is particularly important for protecting neurons against various insults including oxidative stress and excitotoxicity[9].
14-3-3 proteins interact with SMAD proteins in the TGF-β (transforming growth factor-beta) pathway, modulating both canonical and non-canonical signaling[5:3].
14-3-3 proteins play important roles in synaptic plasticity and neurotransmission[8:1]:
YWHAH contributes to cellular protein quality control mechanisms:
YWHAH exhibits high expression in various brain regions:
| Region | Expression Level | Primary Cell Types |
|---|---|---|
| Cerebral Cortex | High | Pyramidal neurons, interneurons, astrocytes |
| Hippocampus | High | CA1/CA3 pyramidal cells, dentate gyrus granule cells |
| Cerebellum | High | Purkinje cells, granule cells |
| Substantia Nigra | Moderate-High | Dopaminergic neurons |
| Basal Ganglia | Moderate | Medium spiny neurons |
| Thalamus | Moderate | Various neuronal populations |
Within neurons, 14-3-3 eta localizes to:
YWHAH is also expressed in glial cells:
14-3-3 proteins are strongly implicated in Alzheimer's disease pathogenesis through multiple mechanisms[10]:
The tau protein, which forms neurofibrillary tangles in AD, interacts with 14-3-3 proteins in several ways[11]:
14-3-3 proteins modulate amyloid-beta (Aβ)-induced neuronal damage[9:1]:
Elevated 14-3-3 protein levels in cerebrospinal fluid (CSF) have been detected in AD patients[12]:
Polymorphisms in YWHAH have been associated with AD risk[13]:
14-3-3 proteins play complex roles in PD pathogenesis[14]:
The interaction between 14-3-3 proteins and alpha-synuclein (SNCA is particularly relevant to PD:
14-3-3 proteins protect dopaminergic neurons in the substantia nigra:
14-3-3 proteins interact with LRRK2, a PD-associated kinase:
14-3-3 proteins, including eta isoform, are implicated in schizophrenia[15]:
CSF 14-3-3 proteins serve as a diagnostic biomarker for CJD[16]:
Several functional polymorphisms in YWHAH have been described:
| SNP | Location | Potential Impact |
|---|---|---|
| rs11549653 | Promoter | Expression regulation |
| rs2270844 | Coding (non-synonymous) | Protein function |
| rs3859539 | 3' UTR | mRNA stability |
GWAS and candidate gene studies have identified YWHAH variants in:
YWHAH interacts with numerous protein partners:
In vitro approaches:
In vivo models:
Human studies:
14-3-3 proteins in CSF represent promising biomarkers:
Modulating 14-3-3 function could provide therapeutic benefits:
14-3-3 proteins are highly conserved across species:
| Species | YWHAH Ortholog | Identity |
|---|---|---|
| Human | YWHAH | 100% |
| Mouse | Ywhah | 96% |
| Rat | Ywhah | 95% |
| Zebrafish | ywhah | 78% |
| D. melanogaster | 14-3-3ε | 72% |
| C. elegans | YWHAH | 65% |
14-3-3 alterations may manifest as:
Foote M, Zhou Y. 14-3-3 proteins in neurological disorders. Trends in Neurosciences. 2020. ↩︎
Yau W, et al. 14-3-3 isoforms in neurodegenerative diseases. Journal of Neural Transmission. 2015. ↩︎ ↩︎
Steinacker P, et al. Neuronal 14-3-3 proteins. Journal of Neural Transmission. 2011. ↩︎
Satoh J, et al. 14-3-3 proteins in brain. Acta Neuropathologica. 2007. ↩︎
Chen X, et al. Molecular mechanisms of 14-3-3 protein function. Cellular and Molecular Life Sciences. 2021. ↩︎ ↩︎ ↩︎ ↩︎
Wang JZ, et al. 14-3-3 proteins in neuronal apoptosis. Neuroscience. 2019. ↩︎ ↩︎
Kim H, et al. 14-3-3 and neuronal survival. Cell Death Discovery. 2020. ↩︎ ↩︎
Dunning C, et al. 14-3-3 adapter proteins in synaptic plasticity. Current Opinion in Neurobiology. 2022. ↩︎ ↩︎
Yang L, et al. 14-3-3 proteins in amyloid-beta induced neuronal damage. Aging Cell. 2024. ↩︎ ↩︎
Umahara T, et al. 14-3-3 proteins in Alzheimer's disease. Neurobiology of Aging. 2004. ↩︎
Shen X, et al. 14-3-3 eta mediates tau-induced neurotoxicity. Cell Death and Disease. 2021. ↩︎
Benzinger A, et al. CSF 14-3-3 biomarkers. Lancet Neurology. 2005. ↩︎
Park J, et al. YWHAH polymorphism and Alzheimer's disease susceptibility. Journal of Alzheimer's Disease. 2022. ↩︎
Xu J, et al. 14-3-3 proteins in Parkinson's disease pathogenesis. Journal of Neurochemistry. 2023. ↩︎
Agorastos A, et al. 14-3-3 proteins in stress-related psychiatric disorders. Molecular Psychiatry. 2022. ↩︎
Liu Y, et al. CSF 14-3-3 eta as a biomarker for Creutzfeldt-Jakob disease. Neurology. 2023. ↩︎
Calandra A, et al. 14-3-3 proteins in neuroinflammation. Frontiers in Immunology. 2022. ↩︎